ReviewJournal of autoimmunity2020
Autoinflammatory and autoimmune conditions at the crossroad of COVID-19.
Review in Journal of autoimmunity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 181 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
181 citing papers in PubMed, 3 syntheses or guidelines pooled it, 313 citations in OpenAlex.
- The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 - A systematic review of the literature.Journal of autoimmunity · 2021Pooled it
- Pooled it
- Autoimmune and Rheumatic Manifestations Associated With COVID-19 in Adults: An Updated Systematic Review.Frontiers in immunologyPooled it
- COVID-19 convalescent plasma composition and immunological effects in severe patients.Journal of autoimmunity · 2021Trial
- Safety and Changes in Health-Related Quality of Life After Epidural Oxygen Injection for Long COVID/Post-COVID Syndrome: A Multicenter Retrospective Study.Journal of clinical medicine · 2026Article
- Multiscale bone remodeling in COVID-19: from osteoimmune signaling to structural and mechanical impairment.Frontiers in bioengineering and biotechnology · 2026Review
- An Intriguing Case Report of Type 2 Autoimmune Polyendocrine Syndrome Post-SARS-CoV-2: Cause or Coincidence?Endocrine, metabolic & immune disorders drug targets · 2026Review
- Article
- Acute haemorrhagic necrotizing encephalopathy and inflammatory demyelinating encephalopathy associated with COVID-19 in adults in Southern China.BMC infectious diseases · 2025Article
- Pediatric autoimmune diseases in the light of COVID-19 pandemic, A retrospective observational big data study.Journal of translational autoimmunity · 2025Article
- The changes in global burden of autoimmune diseases two years after the COVID-19 pandemic: a trend analysis based on the Global Burden of Disease Study 2021.Journal of translational autoimmunity · 2025Review
- Autoimmune hepatitis under the COVID-19 veil: an analysis of the nature of potential associations.Frontiers in immunology · 2025Review
- Observational
- COVID-19 Challenges in Autoimmune Hepatitis Management: A Successful Outcome With Intravenous Immune Globulin (IVIg).Case reports in gastrointestinal medicine · 2025Article
- The effect of the pandemic on autoantibody rates in the general population.Archives of rheumatology · 2024Article
- Clinical Manifestation of Alopecia Areata After COVID-19 Infection or Vaccination.Annals of dermatology · 2024Article
- Autoimmunity in centenarians. A paradox.Journal of translational autoimmunity · 2024Review
- Onset of acute severe autoimmune hepatitis after severe acute respiratory syndrome coronavirus 2 infection: a case report.The Journal of international medical research · 2024Article
- Multiplex Detection of RNA Viruses Based on Ligation Reaction and Universal PCR Amplification.Current microbiology · 2024Article
- Antibodies directed against bacterial antigens in sera of Polish patients with primary biliary cholangitis.Frontiers in cellular and infection microbiology · 2024Article
121 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) has been categorized as evolving in overlapping phases. First, there is a viral phase that may well be asymptomatic or mild in the majority, perhaps 80% of patients. The pathophysiological mechanisms resulting in minimal disease in this initial phase are not well known. In the remaining 20% of cases, the disease may become severe and/or critical. In most patients of this latter group, there is a phase characterized by the hyperresponsiveness of the immune system. A third phase corresponds to a state of hypercoagulability. Finally, in the fourth stage organ injury and failure occur. Appearance of autoinflammatory/autoimmune phenomena in patients with COVID-19 calls attention for the development of new strategies for the management of life-threatening conditions in critically ill patients. Antiphospholipid syndrome, autoimmune cytopenia, Guillain-Barré syndrome and Kawasaki disease have each been reported in patients with COVID-19. Here we present a scoping review of the relevant immunological findings in COVID-19 as well as the current reports about autoinflammatory/autoimmune conditions associated with the disease. These observations have crucial therapeutic implications since immunomodulatory drugs are at present the most likely best candidates for COVID-19 therapy. Clinicians should be aware of these conditions in patients with COVID-19, and these observations should be considered in the current development of vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.